Understanding DHODH Inhibition

Therapeutic Mechanisms of Action of JBZ-001

On top of the expected nucleotide depletion-induced cell stress, our DHODH inhibitor, JBZ-001, displays multiple mechanisms of action, broadening its potential clinical applications, including:

Explore JBZ-001’s Therapeutic Effects:

Biological Effect

Increased Expression of CD47 Expression on Cancer Cells

JBZ-001 upregulates the expression of CD47 on cancer cells, a key “Don’t Eat Me” signal that is targeted by anti-CD47 antibodies. This increased expression enhances the visibility of cancer cells to immune checkpoint inhibitors designed to block CD47, allowing immune cells to recognize and destroy the cancer cells more effectively.

Therapeutic Significance

Potent Synergy with CD47-Targeting Checkpoints

By boosting CD47 expression, JBZ-001 enhances the therapeutic activity of anti-CD47 antibodies, which are designed to block this immune evasion mechanism. This synergistic effect with CD47-targeting therapies could significantly improve the efficacy of immunotherapy in cancers that exploit the CD47 pathway. View our pipeline.

To learn more, explore our preclinical data > here.

To learn more, explore our preclinical data > here.